SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI
JACC: Cardiovascular Interventions · 2026-07 · 19 (14) · 1879-1891
DOI: 10.1016/j.jcin.2026.04.017 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026-07. Verfasst von Ki Hong Choi und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of M…. Hauptthemen laut MEDLINE: Ventricular Remodeling, Sodium-Glucose Transporter 2 Inhibitors, Ventricular Function, Left, Benzhydryl Compounds. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Korean Society of Cardiology.
Abstract (Originalsprache)
BACKGROUND: Although recent large-scale randomized trials have demonstrated that sodium-glucose cotransporter 2 (SGLT2) inhibitors following acute myocardial infarction (AMI) are safe, the mechanisms underlying their potential cardioprotective effects remain poorly understood. OBJECTIVES: The aim of this study was to evaluate the effects of SGLT2 inhibitor therapy on myocardial injury and left ventricular (LV) remodeling in AMI patients undergoing percutaneous coronary intervention (PCI), using cardiac magnetic resonance imaging (CMR). METHODS: In this prospective, open-label, randomized controlled trial, patients ≥18 years of age at high risk for heart failure after successful PCI for AMI were randomly assigned to receive empagliflozin 10 mg once daily or not. The primary endpoint was infarct size (% LV mass) assessed by CMR at 6-month follow-up. The coprimary endpoint was a difference in LV end-systolic volume measured by CMR between baseline and 6 months (ΔLV end-systolic volume). RESULTS: A total of 200 patients underwent randomization, with 100 assigned to the SGLT2 inhibitor group and 100 assigned to the control group. CMR assessments for 6 months were available for 169 patients (84.0%) of the total study population (89 patients in the SGLT2 inhibitor group and 80 patients in the control group). Compared with control, SGLT2 inhibition did not reduce infarct size (% LV mass) at 6-month follow-up (SGLT2 inhibitor vs control, 12.5% [8.5%-20.9%] vs 12.9% [5.0%-20.7%]; P = 0.92). There was no significant difference in ΔLV end-systolic volume between the 2 groups (SGLT2 inhibitor vs control, -3.3% [-19.7% to 13.6%] vs -6.8% [-23.4% to 10.6%]; P = 0.40). CONCLUSIONS: Among patients with AMI undergoing PCI who were at high risk for heart failure, SGLT2 inhibitor use did not reduce infarct size or facilitate reverse LV remodeling at 6 months as assessed by CMR. (Peri-Treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention [PRESTIGE-AMI]; NCT04899479).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Cardiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
- Department of Radiology, Cardiovascular Imaging Center, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Radiology and the Research Institute of Radiology, Asan Medical Center, Seoul, Republic of Korea.
- Department of Radiology and Biomedical Engineering, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea.
- Department of Cardiology, Chonnam National University Hospital, Chonnam National University Medical School, Gwangju, Republic of Korea. Electronic address: hyj200@hanmail.net.
Förderung
- Korean Society of Cardiology
Zitieren
APA
Choi, K. H., Lee, S. H., Kim, S. M., Hong, D., Lee, S. Y., Lee, J. M., Park, T. K., Yang, J. H., Ahn, J. H., Lim, Y., Hyun, D. Y., Cho, K. H., Kim, M. C., Lee, J. E., Kim, Y. H., Hahn, J. Y., Choi, S. H., Gwon, H. C., Ahn, Y., …, & Song, Y. B. (2026). SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI. JACC: Cardiovascular Interventions, 19(14), 1879-1891. https://doi.org/10.1016/j.jcin.2026.04.017
Vancouver
Choi KH, Lee SH, Kim SM, Hong D, Lee SY, Lee JM, et al. SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI. JACC: Cardiovascular Interventions. 2026;19(14):1879-1891. doi:10.1016/j.jcin.2026.04.017
BibTeX
@article{Choi2026,
author = {Choi, Ki Hong and Lee, Seung Hun and Kim, Sung Mok and Hong, David and Lee, Sang Yoon and Lee, Joo Myung and Park, Taek Kyu and Yang, Jeong Hoon and Ahn, Joon Ho and Lim, Yongwhan and Hyun, Dae Young and Cho, Kyung Hoon and Kim, Min Chul and Lee, Jong Eun and Kim, Yun-Hyeon and Hahn, Joo-Yong and Choi, Seung-Hyuk and Gwon, Hyeon-Cheol and Ahn, Youngkeun and Hong, Young Joon and Song, Young Bin},
title = {SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
volume = {19},
number = {14},
pages = {1879--1891},
doi = {10.1016/j.jcin.2026.04.017}
}
EUVIMED